Ying Zhou1,2, Yingying Qiao3, Ian M Adcock4, Jun Zhou5, Xin Yao6. 1. Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. 2. Department of Respiratory Medicine, Nanjing Gulou Group Anqing Petrochemical Hospital, 11 Shihua First Road, Anqing, 246002, China. 3. Department of Respiratory Medicine, The Third Affiliated Hospital of Suzhou University, 185 Juqian Street, Changzhou, 213003, China. 4. Airway Disease Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK. 5. Department of Respiratory Medicine, The Third Affiliated Hospital of Suzhou University, 185 Juqian Street, Changzhou, 213003, China. zhouyfan@126.com. 6. Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. yaoxin@njmu.edu.cn.
Abstract
PURPOSE: Found in inflammatory zone 2 (FIZZ2) is associated with lung inflammation. The aim of the study was to investigate the expression and utility of FIZZ2 as a marker for chronic obstructive pulmonary disease (COPD). METHODS: Immunohistochemistry was used to detect the expression of FIZZ2 in COPD. The serum concentration of FIZZ2 was measured by enzyme-linked immunosorbent assay and the episodes of acute exacerbations of COPD (AECOPD) in the following year were recorded. RESULTS: FIZZ2 expression was elevated in bronchial epithelial cells (0.217 ± 0.021 vs 0.099 ± 0.010, p < 0.0001) and negatively correlated with the pulmonary function (FEV1/FVC%) (p = 0.0149) and positively correlated with the smoking index (p = 0.0241). Serum level of FIZZ2 in COPD were significantly higher than that in healthy controls (561.6 ± 70.71 vs 52.24 ± 20.52 pg/ml, p < 0.0001) and increased with the COPD severity. Serum levels of FIZZ2 negatively correlated with the pulmonary function [Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1), FEV1%, FEV1/FVC) (r = - 0.3086, - 0.3529, - 0.3343, and - 0.2676, respectively, p = 0.0003, p < 0.0001, p < 0.0001, p = 0.0014). The expression of human serum FIZZ2 was positively correlated with the smoking index (r = 0.2749, p = 0.0015). There was a positive correlation between the FIZZ2 concentration and the frequency of AECOPD episodes in the following year (r = 0.7291, p < 0.0001). CONCLUSION: FIZZ2 expression was elevated in patients with COPD and its serum concentration might be a potential biomarker for AECOPD.
PURPOSE: Found in inflammatory zone 2 (FIZZ2) is associated with lung inflammation. The aim of the study was to investigate the expression and utility of FIZZ2 as a marker for chronic obstructive pulmonary disease (COPD). METHODS: Immunohistochemistry was used to detect the expression of FIZZ2 in COPD. The serum concentration of FIZZ2 was measured by enzyme-linked immunosorbent assay and the episodes of acute exacerbations of COPD (AECOPD) in the following year were recorded. RESULTS: FIZZ2 expression was elevated in bronchial epithelial cells (0.217 ± 0.021 vs 0.099 ± 0.010, p < 0.0001) and negatively correlated with the pulmonary function (FEV1/FVC%) (p = 0.0149) and positively correlated with the smoking index (p = 0.0241). Serum level of FIZZ2 in COPD were significantly higher than that in healthy controls (561.6 ± 70.71 vs 52.24 ± 20.52 pg/ml, p < 0.0001) and increased with the COPD severity. Serum levels of FIZZ2 negatively correlated with the pulmonary function [Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1), FEV1%, FEV1/FVC) (r = - 0.3086, - 0.3529, - 0.3343, and - 0.2676, respectively, p = 0.0003, p < 0.0001, p < 0.0001, p = 0.0014). The expression of human serum FIZZ2 was positively correlated with the smoking index (r = 0.2749, p = 0.0015). There was a positive correlation between the FIZZ2 concentration and the frequency of AECOPD episodes in the following year (r = 0.7291, p < 0.0001). CONCLUSION: FIZZ2 expression was elevated in patients with COPD and its serum concentration might be a potential biomarker for AECOPD.
Authors: Wen Qi Gan; J Mark FitzGerald; Chris Carlsten; Mohsen Sadatsafavi; Michael Brauer Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Amir Khakban; Don D Sin; J Mark FitzGerald; Bruce M McManus; Raymond Ng; Zsuzsanna Hollander; Mohsen Sadatsafavi Journal: Am J Respir Crit Care Med Date: 2017-02-01 Impact factor: 21.405
Authors: I N Holcomb; R C Kabakoff; B Chan; T W Baker; A Gurney; W Henzel; C Nelson; H B Lowman; B D Wright; N J Skelton; G D Frantz; D B Tumas; F V Peale; D L Shelton; C C Hébert Journal: EMBO J Date: 2000-08-01 Impact factor: 11.598
Authors: Anil Mishra; Meiqin Wang; James Schlotman; Nikolaos M Nikolaidis; Charles W DeBrosse; Margaret L Karow; Marc E Rothenberg Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-06-01 Impact factor: 5.464
Authors: C L Fang; L J Yin; S Sharma; S Kierstein; H F Wu; G Eid; A Haczku; C J Corrigan; S Ying Journal: Clin Exp Allergy Date: 2015-05 Impact factor: 5.018